<DOC>
	<DOCNO>NCT01317589</DOCNO>
	<brief_summary>Background study : Treatment Pain Head-and-Neck Cancer Patients : methadone effective fentanyl ? Pain prevalent symptom patient cancer . A neuropathic component see one third patient . In patient head-and-neck cancer neuropathic pain far prevalent general cancer population : 46-64 % . Treatment neuropathic pain complex available treatment modality achieve ( partial ) pain relief 40-60 % patient . The N-Methyl-D-Aspartate Receptor ( NMDAR ) play central role mediation neuropathic pain . NMDAR blocker could new approach treat neuropathic pain patient cancer . Methadone strong opioid time significant non-competitive NMDA-receptor antagonist quality describe . Many small study case-reports describe successful rotation different strong opioids methadone . There study select patient ( predominantly ) neuropathic pain treat methadone , whereas group patient expected profit NMDAR-antagonist property methadone . Objective study : This randomise control trial ( RCT ) aim investigate whether addition NMDAR-antagonist strong opioid ( methadone ) superior treatment predominantly neuropathic pain strong opioid alone ( fentanyl ) term pain relief time achieve significant pain relief . Study design : Open label randomise control trial Study population : opioid naïve patient histological proven head-and-neck cancer ( partly ) neuropathic pain NRS score ≥ 4 , age =/ &gt; 18 year Intervention Treatment methadone fentanyl patch Primary study parameters/outcome study : Is methadone effective fentanyl treatment pain patient head-and-neck cancer respect 1. significant pain relief ( reduction Numeric Rating Scale ( NRS ) 50 % ) 2. pain interference Secondary study parameters/outcome study : Is methadone superior fentanyl treatment pain patient head-and-neck cancer respect 1. time achieve significant pain relief 2. side-effect profile ?</brief_summary>
	<brief_title>Treatment Pain Head-and-Neck Cancer Patients : Methadone More Effective ?</brief_title>
	<detailed_description>Study design The duration study 9 week . Patients visit outpatient clinic 5 time . Patients MAASTRO clinic see directly radiation therapy . No extra visit necessary . T= -1 : - inform consent - sort pain ( DN4 ) - randomisation T = 0 - questionnaire 1 : demographic variable , disease specific variable , BPI , side effect question , HADS , QoL - explain provide pain sheet - start methadone 2 x 2,5 mg fentanyl patch 12 μg/uur - breakthrough medication : 50 µg fentanyl nose spray fentanyl stick 400 µg till 6x/day T=1 - questionnaire 2 : BPI , side effect question , global perceive effect 1 week - review pain sheet pain total rescue dos - necessary increase dose strong opioid 50 % T=2 - questionnaire 2 : BPI , side effect question , global perceive effect 3 week - review pain sheet pain total rescue dos - necessary increase dose strong opioid 50 % - necessary decrease dose strong opioid 30 % T=3 - questionnaire 2 : BPI , side effect question , global perceive effect 5 week - review pain sheet pain total rescue dos - necessary increase dose strong opioid 50 % - necessary decrease dose strong opioid 30 % T = 4 - questionnaire 3 : BPI , side effect question , global perceive effect , QoL - necessary increase dose strong opioid 50 % - necessary decrease dose strong opioid 30 %</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>opioid naive patient histological proven headandneck cancer ( partly ) neuropathic pain NRS score =/ &gt; 4 age 18 able read fill questionnaires recent operation ( le 7 day ) woman childbearing potential use contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Pain</keyword>
	<keyword>Cancer Head Neck</keyword>
	<keyword>methadone</keyword>
	<keyword>Fentanyl</keyword>
</DOC>